Efficacy

Polivy (polatuzumab vedotin-piiq) for Lymphoma

Polivy (polatuzumab vedotin-piiq) is a targeted cancer medicine that is used in combination with other drugs to treat certain types of lymphoma. Specifically, it is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), which is the most common type of non-Hodgkin lymphoma. Polivy works by attaching to a protein called CD79b found on the surface of B cells, including DLBCL cells, and delivering a potent cytotoxic agent directly to these cells. This targeted approach helps to minimize the impact on healthy cells.

The efficacy of Polivy was demonstrated in a pivotal clinical trial that showed significant improvement in the overall response rate (ORR) and complete response rate (CRR) when used in combination with bendamustine and rituximab (BR) compared to BR alone. Patients treated with the Polivy combination regimen experienced a higher rate of complete remission, which is a significant indicator of efficacy in lymphoma treatment. The trial results supported the accelerated approval of Polivy by regulatory agencies for the treatment of DLBCL after at least two prior therapies.

Tazverik (tazemetostat) for Lymphoma

Tazverik (tazemetostat) is an orally administered medication approved for the treatment of certain types of lymphoma. It is specifically approved for adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation and who have received at least two prior systemic therapies. Tazverik is also indicated for FL patients who have no satisfactory alternative treatment options, regardless of EZH2 mutation status. Tazverik inhibits the activity of the EZH2 enzyme, which can play a role in the development and progression of cancer cells.

The efficacy of Tazverik in treating lymphoma was established through clinical trials that evaluated its use in patients with relapsed or refractory FL. The trials demonstrated a meaningful ORR with a duration of response ranging from several months to over a year in some cases. The approval of Tazverik was based on these efficacy outcomes, providing a novel treatment option for patients with FL who have exhausted other therapies. The drug's efficacy, along with its oral administration route, makes it a valuable addition to the treatment landscape for lymphoma.